Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company that regularly issues news and regulatory updates related to its immune medicine platform, Minimal Residual Disease (MRD) business, and Immune Medicine programs. News about Adaptive Biotechnologies often highlights developments in its clonoSEQ MRD test, financial performance, scientific data presentations, and collaborations with biopharmaceutical partners.
Investors and clinicians following ADPT news can expect updates on MRD revenue trends, clonoSEQ testing volumes, and segment-level financial results, as reported in the company’s earnings press releases and accompanying Form 8-K filings. The company’s disclosures describe MRD as a key growth area, with clonoSEQ adoption and MRD revenue metrics frequently discussed in quarterly results and preliminary financial announcements.
Adaptive Biotechnologies also reports on scientific and medical conference activity, including presentations at meetings such as the American Society of Hematology (ASH) Annual Meeting. News coverage has described numerous abstracts featuring clonoSEQ data across multiple blood cancers, with a focus on how MRD assessment informs treatment decisions, evaluates depth of response, and supports clinical research in hematologic oncology.
In addition, ADPT news includes information on corporate and partnering events, such as participation in healthcare and investor conferences and agreements with pharmaceutical companies to use Adaptive’s immune medicine platform and immune receptor–antigen datasets. These items provide insight into how the company applies its technology in collaborations, target discovery efforts, and AI-enabled research. For ongoing context on Adaptive Biotechnologies’ MRD business, Immune Medicine initiatives, and regulatory disclosures, readers can review the continuing stream of press releases and SEC-referenced announcements associated with the ADPT symbol.
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in early 2026: the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026, and a Fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston, MA on Monday, March 2, 2026 at 11:50 a.m. ET.
Interested parties may access live and archived webcasts of both sessions via the Investors section of the company website at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026. Management will host a conference call and webcast beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors website and the webcast will be archived for replay within 24 hours.
Investors can listen via the company website at www.adaptivebiotech.com and should check the Investors section for the live link and replay.
Adaptive Biotechnologies (Nasdaq: ADPT) reported preliminary, unaudited fourth quarter and full year 2025 results. Total revenue was approximately $72M in Q4 and $277M for FY2025, up 51% and 55% year‑over‑year. MRD revenue was about $62M in Q4 and $212M for the year, up 54% and 46% versus 2024; excluding an MRD regulatory milestone, MRD revenue grew 45% FY‑over‑FY. clonoSEQ tests delivered totaled ~30,000 in Q4 (+43%) and ~105,600 for the year (+39%). Cash and marketable securities were ~$227M at year end. Full audited results will be released during the February 2026 earnings call.
Adaptive Biotechnologies (Nasdaq: ADPT) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management is scheduled to present on Monday, January 12, 2026 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast will be available on the company’s Investors website at www.adaptivebiotech.com.
Adaptive Biotechnologies (NASDAQ: ADPT) announced two non-exclusive agreements with Pfizer on Dec 15, 2025: a target discovery collaboration to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis (RA) using Pfizer clinical samples, and a data licensing deal giving Pfizer access to Adaptive’s TCR-antigen datasets for AI/ML model training across immunology programs.
Adaptive will lead RA target discovery while Pfizer handles development and commercialization. Adaptive will receive an upfront payment and may earn additional milestone and licensing fees, with RA-related milestones potentially totaling about $890 million; specific financial terms are not disclosed.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that Dr. Harlan Robins, Chief Scientific Officer and Co‑Founder, and Susan Bobulsky, Chief Commercial Officer, MRD, will participate in a Jefferies fireside chat on Minimal Residual Disease (MRD) in hematology/oncology with a deep dive into the clonoSEQ assay technology.
The session is scheduled for Thursday, December 11, 2025, 2:00 p.m. to 3:00 p.m. ET. Interested parties may contact their Jefferies sales representative for participation details.
Adaptive Biotechnologies (Nasdaq: ADPT) announced expanded clinical use of its clonoSEQ measurable residual disease (MRD) test at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.
Key highlights: 90 abstracts feature clonoSEQ data, including 17 showing MRD-guided clinical interventions. The phase II EndRAD study reported that 51 NGS MRD-negative B-ALL patients receiving non-TBI transplant conditioning had outstanding event-free and overall survival comparable to standard TBI approaches. Additional data include 200-patient AURIGA MRD dynamics, intensified maintenance doubling MRD-negativity, and an 80-patient CLL cohort showing deep remissions at a 10^-6 MRD threshold.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that its next-generation sequencing clonoSEQ® MRD test is featured in 89 abstracts, including 36 oral presentations, at the 67th ASH Annual Meeting scheduled for Dec. 6–9, 2025 in Orlando.
Abstracts cover multiple myeloma, ALL, CLL, MCL, DLBCL and other blood cancers, with more than 17 presentations showing clonoSEQ informing real-world treatment decisions and expanded use in clinical trials across modalities such as CAR T and bispecific antibodies.
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in late 2025: a presentation at the Jefferies Global Healthcare Conference in London on November 19, 2025 at 8:00 a.m. GMT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 8:30 a.m. ET.
Interested parties may access live and archived webcasts on the company’s Investors section at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) reported third quarter 2025 results on November 5, 2025, showing strong MRD momentum and updated guidance.
Key points: Q3 revenue $94.0M (includes $33.7M one-time Genentech amortization); excluding Genentech $60.2M (+40% YoY). MRD revenue $56.8M (+52% YoY) with clonoSEQ volume 27,111 (+38% YoY). MRD achieved cash flow positivity and an MRD Adjusted EBITDA of $7.0M. Company Adjusted EBITDA was $28.0M. Cash and marketable securities were $216.8M. Company raised full-year MRD guidance to $202–$207M and narrowed operating spend and cash burn guidance.
FAQ
What is the current stock price of Adaptive Biotechnologies (ADPT)?
What is the market cap of Adaptive Biotechnologies (ADPT)?
